Edwards Lifesciences (NYSE:EW) Releases Earnings Results, Beats Expectations By $0.04 EPS

Edwards Lifesciences (NYSE:EW) announced its quarterly earnings results on Tuesday. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04, Zacks reports. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences updated its FY 2025 guidance to 2.400-2.500 EPS and its Q1 2025 guidance to 0.580-0.640 EPS.

Edwards Lifesciences Price Performance

EW stock traded down $0.15 during midday trading on Tuesday, reaching $70.95. The company had a trading volume of 3,346,843 shares, compared to its average volume of 4,396,275. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market capitalization of $41.85 billion, a price-to-earnings ratio of 10.24, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12. The stock has a 50 day moving average price of $72.46 and a 200-day moving average price of $69.26.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on EW shares. Robert W. Baird lowered their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Royal Bank of Canada increased their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. Barclays increased their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. Finally, Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $79.19.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,000 shares of company stock valued at $547,430. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.